In combination with immune checkpoint inhibitors, such as PD-1/PD-L1 antagonists, entinostat enhanced the anti-tumoral effects of PD-1 inhibition in two syngeneic mouse models for lung and renal cell carcinoma [159]. The gene discussed is CD274; the disease is renal cell carcinoma.